SCHEMBL22200709

SCHEMBL22200709

CC(C)n1c(=O)c(-c2ccc(N)c(F)c2)nc2cnc(N)nc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5B Q9UGL1 1/20 0.45
CYP1A2 P05177 9/20 0.44
CYP3A4 P08684 8/20 0.44
USP2 O75604 5/20 0.44
HSD17B10 Q99714 4/20 0.44
ALDH1A1 P00352 3/20 0.44
MTOR P42345 6/20 0.44
CYP2C9 P11712 3/20 0.39
CYP2C19 P33261 3/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
ERN1 O75460 2/20 0.39
TSHR P16473 3/20 0.39
PIK3CA P42336 3/20 0.39
RICTOR Q6R327 1/20 0.38
RPTOR Q8N122 1/20 0.38
MAPKAP1 Q9BPZ7 1/20 0.38
MLST8 Q9BVC4 1/20 0.38
PIK3CD O00329 1/20 0.38
MAPK1 P28482 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22190728 0.88 KDM5B (0.43) KDM5BCYP1A2CYP3A4USP2HSD17B10
SCHEMBL29356116 0.88 KDM5B (0.43) KDM5BCYP1A2CYP3A4USP2HSD17B10
SCHEMBL22200463 0.87 MTOR (0.44) CYP1A2CYP3A4USP2HSD17B10ALDH1A1
SCHEMBL25035485 0.82 ERN1 (0.48) CYP1A2CYP3A4USP2HSD17B10ALDH1A1
SCHEMBL22200437 0.81 MTOR (0.52) CYP1A2CYP3A4USP2HSD17B10ALDH1A1
SCHEMBL22200352 0.81 ERN1 (0.40) CYP1A2CYP3A4USP2HSD17B10ALDH1A1
SCHEMBL25035391 0.81 ERN1 (0.40) CYP1A2CYP3A4USP2HSD17B10ALDH1A1
SCHEMBL22200356 0.81 ERN1 (0.41) CYP1A2CYP3A4USP2HSD17B10ALDH1A1
SCHEMBL22200607 0.81 PIK3CA (0.48) KDM5BMTORERN1PIK3CA
SCHEMBL25035568 0.80 ERN1 (0.45) CYP1A2CYP3A4USP2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed